04-APR-2026 6:10

Lung-MAP ACCRUAL REPORT

  O
P
E
N		 ACCR
GOAL		 TOTAL
REGS.		 REGS.
LAST
12
Month		 REGS.
LAST
6
Month		 REGS.
LAST
3
Month		 REGS.
LAST
30
DAYS		 REGS.
LAST
7
DAYS		 DATE OF
FIRST
REG.		 # of
ACT.
INSTs		 # of
CURR
IRBs
LUNGMAP Screening Protocol Registrations
Total     3964 365 202 106 39 8 02/06/2019 472 183
Screened at PD     1464 205 133 75 32 5      
Pre-Screened prior to PD     2479 140 59 27 6 2      
Treatment-naive     21 20 10 4 1 1      
ctDNA Specimen Submission     315 0 0 0 0 0      
Re-analysis Requests     530 29 17 10 2 1      
 
Sub-Study Assignments
LUNGMAP Sub-Study Assignments     2144 384 162 88 36 11      
Screened at PD     1231 234 129 73 31 9      
Pre-Screened prior to PD     835 125 20 9 3 1      
Treatment-naive     21 20 11 5 1 1      
After PD on a Lung_MAP Sub-Study     57 5 2 1 1 0      
 
Sub-Study Assignments (open studies only)
S1800E     343 343 138 74 32 8      
S1900G     35 6 3 2 1 0      
S1900J     18 7 5 3 1 1      
S1900K     38 28 16 9 2 2      
 
Sub-Study Registrations
LUNGMAP Sub-Study Registrations     612 116 75 45 20 5      
Initial sub-study registrations     600 116 75 45 20 5      
Subsequent sub-study registrations     12 0 0 0 0 0      
 
Patients Registered to a Sub-Study (open studies only)
S1800E: Non-Match: Docetaxel + Ramu +/- Cemiplimab   378 85 85 60 36 18 4 05/22/2025 350 111
Docetaxel plus Ramucirumab Y   43 43 30 18 8 1      
Cemiplimab plus Docetaxel and Ramucirumab Y   42 42 30 18 10 3      
S1900G: EGFR-Mut, MET-Amp: Capmat + Osimert +/- Ramu   66 25 7 3 2 1 1 05/05/2023 342 109
Capmatinib + Osimertinib + Ramucirumab Y   14 5 2 1 0 0      
Capmatinib + Osimertinib Y   11 2 1 1 1 1      
S1900J: MET Amplification: Amivantamab Hyaluronidase   88 4 3 2 1 1 0 11/19/2024 242 80
Amivantamab Hyaluronidase Y   4 3 2 1 1 0      
S1900K: MET Exon 14: Tepotinib +/- Ramucirumab   56 24 21 10 6 0 0 08/08/2024 270 89
Tepotinib + Ramucirumab Y   16 14 7 5 0 0      
Tepotinib Y   8 7 3 1 0 0